Denovo Biopharma Plans to Initiate a Global Phase III Trial of DLBCL Drug
February 16, 2017 at 14:30 PM EST
San Diego/Hangzhou-based Denovo Biopharma plans to launch a biomarker driven global Phase III clinical trial for its lead drug DB102 as a first line treatment for diffuse large B-cell lymphoma (DLBCL) patients this year. More details.... Share this with colleagues: // //
